ReviewMedical microbiology and immunology2020
Caenorhabditis elegans as a model animal for investigating fungal pathogenesis.
Review in Medical microbiology and immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Chelerythrine enhances anti-fungi immunity inFrontiers in immunology · 2026Article
- The Interaction Between the Nematode Caenorhabditis elegans and Its Coexisting Fungal Microbiome Member Barnettozyma californica.Environmental microbiology reports · 2025Article
- Brief guide to Caenorhabditis elegans survival assays.Molecules and cells · 2025Review
- Experimental Models and Their Applicability in Inflammation Studies: Rodents, Fish, and Nematodes.International journal of molecular sciences · 2025Review
- Procatechuic acid and protocatechuic aldehyde increase survival ofFrontiers in pharmacology · 2024Article
- A rabbit model of ear otitis established using theVeterinary world · 2023Article
- Eicosapentaenoic acid influences the pathogenesis of Candida albicans in Caenorhabditis elegans via inhibition of hyphal formation and stimulation of the host immune response.Medical microbiology and immunology · 2023Article
- Alternative Non-Mammalian Animal and Cellular Methods for the Study of Host-Fungal Interactions.Journal of fungi (Basel, Switzerland) · 2023Review
- Juxtaposing Caenorhabditis elegans-Pathogenic Mould Model with Other Models; How Reliable Is This Nematode Model? A Mini Review.Current microbiology · 2023Review
- Paeoniflorin mitigates high glucose-induced lifespan reduction by inhibiting insulin signaling inFrontiers in pharmacology · 2023Article
- Immunological pathogenesis of Bovine E. coli infection in a model of C. elegans.BMC microbiology · 2022Article
- Many ways, one microorganism: Several approaches to study Malassezia in interactions with model hosts.PLoS pathogens · 2022Review
- Emerging Antifungal Targets and Strategies.International journal of molecular sciences · 2022Review
- Evaluation ofFrontiers in pharmacology · 2022Article
- Nuclear hormone receptors promote gut and glia detoxifying enzyme induction and protect C. elegans from the mold P. brevicompactum.Cell reports · 2021Article
- Biosafety assessment of Acinetobacter strains isolated from the Three Gorges Reservoir region in nematode Caenorhabditis elegans.Scientific reports · 2021Article
- In Vitro and In Vivo Effect of Peptides Derived from 14-3-3Journal of fungi (Basel, Switzerland) · 2021Article
- Combination Therapy to Treat Fungal Biofilm-Based Infections.International journal of molecular sciences · 2020Review
- Investigation into In Vitro and In VivoMicroorganisms · 2020Article
- Pathogenesis and Clinical Relevance ofFrontiers in microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The morbidity and mortality associated with systemic fungal infections in humans cannot be underestimated. The nematode Caenorhabditis elegans has become popular for the in vivo study of the pathogenesis of human fungal pathogens and as an antifungal drug-screening tool. C. elegans offers many advantages as a model organism for the study of human fungal diseases, including lack of ethics requirements, easy maintenance in the laboratory, fully sequenced genome, availability of genetic mutants, and the possibility of liquid assays for high-throughput antifungal screening. Its major drawbacks include the inability to grow at 37 °C and absence of an adaptive immune response. However, several virulence factors involved in the pathogenesis of medically important fungal pathogens have been identified using the C. elegans model, consequently providing new leads for drug discovery and potential drug targets. We review the use of C. elegans as a model animal to understand the pathogenesis of medically important human fungal pathogens and the discovery of novel antifungal compounds. The review makes a case for C. elegans as a suitable invertebrate model for a plethora of practical applications in the investigation of fungal pathogenesis as well as its amenability for liquid-based high-throughput screening of potential antifungal compounds.
Indexed as
Identifiers
31555911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.